Eli Lilly’s retatrutide reduced knee osteoarthritis pain in phase 3 trials
Researchers disclosed results from two phase 3 trials involving 1,019 adults with overweight or obesity and painful knee osteoarthritis, finding greater weight loss and pain reduction with Eli Lilly’s experimental retatrutide than with placebo. At 68 weeks, knee pain scores fell by at least 50% in 69.6% of participants receiving 9 mg and 63.2% receiving 12 mg, versus 37.8% receiving placebo. Whether the drug changes the progression of joint disease requires further research.